{"filing":{"accession_number":"0001193125-26-350596","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-13","primary_document":"d328636d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/d328636d8k.htm"},"events":[{"id":27764,"run_id":25338,"accession_number":"0001193125-26-350596","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces a clinical trial milestone—dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy conducted in collaboration with Beijing Mabworks Biotech. This is a material operational/strategic event for a biotech company, as Phase 2 advancement represents meaningful progress in drug development. The event does not fit a more specific category (not earnings, M\u0026A, impairment, or litigation), so operational_other is appropriate.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29432,"accession_number":"0001193125-26-350596","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a clinical trial milestone—dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy conducted in collaboration with Beijing Mabworks Biotech. This is a material operational/strategic event for a biotech company, as Phase 2 advancement represents meaningful progress in drug development. The event does not fit a more specific category (not earnings, M\u0026A, impairment, or litigation), so operational_other is appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:31:48.054408+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29432,"accession_number":"0001193125-26-350596","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a clinical trial milestone—dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy conducted in collaboration with Beijing Mabworks Biotech. This is a material operational/strategic event for a biotech company, as Phase 2 advancement represents meaningful progress in drug development. The event does not fit a more specific category (not earnings, M\u0026A, impairment, or litigation), so operational_other is appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:31:48.054408+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-08-14"}]}